Stada CEO discovers he's under surveillance as deal action heats up

Stada's CEO reportedly discovered a recording device in his vehicle and received anonymous photographs depicting himself in personal and business situations. Photo courtesy of Stada.

Amid a flurry of deal action for German drugmaker Stada, local media report that CEO Matthias Wiedenfels was targeted in a spying operation.

Wiedenfels discovered a recording device in his car and received photographs of himself in personal or private business situations, according to Manager Magazin. The alleged spying happened in the second half of 2016.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Stada declined to comment on the developments, according to the magazine.

RELATED: Hot buyout target Stada rolls out cost-cutting measures, new financial forecasts to draw higher bids

The news comes as takeover talks have intensified for the German generics firm, with private equity firms, Chinese pharma companies and Mylan Pharmaceuticals all rumored to be interested in a takeout. Last month, Boston private equity outfit Advent International offered up $3.7 billion, but Stada plans to continue entertaining offers.

Earlier this month, the drugmaker trotted out higher sales forecasts and a cost-cutting strategy in an attempt to draw higher bids. Stada now expects €2.65 billion to €2.7 billion in 2019 sales, up from the €2.6 billion it was previously predicting.

RELATED: Stada's first real bidder has put up a $3.7B offer. Will a bidding war follow?

It’s also making changes in manufacturing and purchasing to take advantage of “significant savings potential.” There’s plenty of reason for potential suitors to be interested in the German drugmaker. With a three-year average operating profit margin lagging most of the generics industry at 11%, a buyer could eke out value by breaking up the business, streamlining its operations or laying off employees.

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.